Related Experiment Video
Updated: May 17, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Investigating the function and targeting of MET protein as an oncogene kinase in pancreatic ductal adenocarcinoma: A
Nahid Askari1, Morteza Hadizadeh2, Mohammad Sina3
1Department of Biotechnology, Institute of Sciences and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran.
Introduction:
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a poor prognosis. Kinase proteins are essential regulators of cellular processes and potential targets for drug development.
Methods:
Integration of multiple microarray datasets was screened to find differentially expressed kinases (DE-Kinases) across adjacent normal and tumor tissue samples in PDAC. The most effective kinase for drug design and docking in this study was selected by investigating biological mechanisms and survival analyses. Forty phytochemicals were extracted from the yellow sweet clover, Melilotus officinalis (Linn.) Pall, and were then subjected to in silico screening and molecular docking studies against a specific potent kinase.
Results:
MET, PAK3, and PDK4 were identified as the DE-Kinases. After examining the pathways and biological processes, up-regulated MET had the most significant survival analysis and became our primary kinase for drug design and docking in this study. Four of the extracted phytocompounds of Melilotus officinalis (Linn.) Pall that exhibited high binding affinities with MET and were selected for toxicity analysis. Finally, the stability and mobility of the two nontoxic compounds that passed the toxicity test (dicumarol PubChem CID: 54676038 and melilotigenin PubChem CID: 14059499) were studied by molecular dynamics simulation.
Conclusion:
This study's results identified two phytochemicals in yellow sweet clover that could be used to develop an anticancer drug, but experimental evaluation is necessary to confirm their efficacy.
Insights
This study identified two anticancer compounds from yellow sweet clover for pancreatic cancer drug development. Further research is needed to confirm their effectiveness against pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Pharmacology
- Bioinformatics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with limited treatment options.
- Kinase proteins are crucial for cellular functions and represent potential therapeutic targets.
Purpose of the Study:
- To identify differentially expressed kinases (DE-Kinases) in PDAC.
- To screen phytochemicals for potential anticancer drug development against PDAC-associated kinases.
Main Methods:
- Microarray data integration to identify DE-Kinases in PDAC.
- In silico screening and molecular docking of phytochemicals from *Melilotus officinalis* against selected kinases.
- Molecular dynamics simulations to assess the stability of potential drug candidates.
Main Results:
- MET, PAK3, and PDK4 were identified as DE-Kinases, with MET showing significant association with patient survival.
- Two non-toxic phytochemicals, dicumarol and melilotigenin, from *Melilotus officinalis* demonstrated high binding affinity to MET.
- Molecular dynamics simulations confirmed the stability and mobility of dicumarol and melilotigenin.
Conclusions:
- Dicumarol and melilotigenin are promising candidates for novel PDAC drug development.
- Experimental validation is required to confirm the therapeutic efficacy of these identified phytochemicals.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway